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Based on the implication of increased muscarinic ACh activity in the production of negative symptoms, the 
association of decreasing cholinergic activity with positive symptoms, and the covariance of positive and 
negative symptoms in the psychotic phase of schizophrenia, a model of (DA) dopaminergic/(ACh) 
cholinergic interactions in schizophrenia was recently formulated. It suggests that DA/ACh balance is of 
central importance in schizophrenic pathophysiology and that muscarinic ACh activity increases in an 
attempt to maintain this balance in the face of increasing DA activity that occurs in the psychotic phase of 
the illness. The model further suggests that the muscarinic system exerts a damping influence on the 
emergence of positive symptoms associated with DA hyperactivity, but that this compensatory increase in 
muscarinic activity is accompanied by an intensification of negative symptoms. In the present study, we 
tested two important postulates of this model. We tested the prediction that muscarinic activity is increased 
in schizophrenia by comparing the effect of biperiden, an antimuscarinic M-l agent, on REM latency in 12 
drug-free schizophrenic inpatients and matched normal controls. We found that biperiden caused a smaller 
increase in REM latency in schizophrenic patients, suggesting that muscarinic activity is increased in 
schizophrenia. We tested the prediction that an anticholinergic agent would increase positive symptoms and 
decrease negative symptoms by studying the effect of 8 mg of biperidenday for 2 days on positive and 
negative symptoms (assessed by the BPRS) in 30 medication-free schizophrenic inpatients. Biperiden 
produced a significant increase in positive symptoms (t= 6.36, df= 29, P-C 0.001) and reduction in negative 
symptoms (t= - 2.05, df= 29, P< 0.05). These findings suggest that central muscarinic activity is increased 
in the psychotic phase of schizophrenia and is relevant to the expression of positive and negative symptoms. 
KeJ +twrds: Cholinergic: Symptoms; Psychotic; Pharmacology; Sleep; (Schizophrenia) 
INTRODUCTION 
The cholinergic system has intermittently been 
suspected of being involved in the pathophysi- 
ology of schizophrenia, but its precise role has 
been inadequately investigated and is still poorly 
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understood. Some of the earliest pharmacological 
interventions in schizophrenia actually involved 
manipulation of the cholinergic system with anti- 
cholinergic agents such as hyoscine (Kraepelin. 
1919) and atropine (Forrer and Miller, 1958) or 
cholinergic stimulation with acetylcholine (Cohen 
et al., 1944) and arecoline (Pfeiffer and Jenney, 
1957). Despite these historical precedents, cholin- 
ergic mechanisms currently are considered rela- 
tively unimportant in schizophrenia and primarily 
discussed with regard to undesirable extrapyrami- 
da1 side effects of neuroleptics. Evidence from 
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several lines of research, however, suggests that 
this viewpoint warrants reconsideration and that 
the cholinergic system may play a prominent role 
in schizophrenic pathophysiology (Tandon and 
Greden, 1989). 
Centrally active cholinomimetic agents and 
cholinesterase inhibitors lead to behavioural syn- 
dromes strikingly similar to the negative schizo- 
phrenic syndrome (Davis et al., 1976; Greden et al., 
1987), anticholinergic agents may alleviate nega- 
tive symptoms (Fayen et al., 1988; Tandon et al., 
1988, 1990a), schizophrenic patients with negative 
symptoms tend to ‘abuse’ anticholinergics and 
report activating and energizing effects (Fisch, 
1987; Wells et al., 1989), shortened REM latency in 
schizophrenia (Zarcone et al., 1987: Douglass et 
al.. 1989) appears to be related to the severity of 
. negative symptoms (Tandon et al., 1989a), and 
post-dexamethasone cortisol levels are directly cor- 
related to the severity of negative symptoms (Safer 
et al., 198.5; Faustman et al., 1989; Tandon et al.. 
1989b). Both short REM latency and increased 
post-dexamethasone cortisol levels are consistent 
with increased cholinergic activity (Sitaram et al., 
1979; Carroll et al., 1980; Berger et al.. 1989). 
Collectively, these data implicate increased cholin- 
ergic muscarinic activity in the production of nega- 
tive symptoms (Tandon and Greden, 1989, 1990). 
On the other hand, anticholinergics may antago- 
nize the therapeutic effects of neuroleptics specifi- 
cally with regard to positive symptoms (Johnstone 
et al., 1983, 1988; Singh et al., 1987). anticholiner- 
gics exacerbate positive symptoms in drug-free 
schizophrenic patients (Tandon et al., 1990a), and 
physostigmine reverses the increase in positive 
schizophrenic symptoms induced by methylpheni- 
date (Janowsky et al., 1973). These data indicate an 
association between decreasing cholinergic activity 
and positive symptoms. 
In an effort to explain these findings and explain 
the covariance of positive and negative symptoms 
with neuroleptic treatment (Van Kammen et al., 
1987; Tandon et al., 1990b), Tandon and Greden 
(1989) proposed a model of dopaminergic/cholin- 
ergic interactions in schizophrenia that suggests: 
(a) cholinergicjdopaminergic huluncr is of central 
importance in schizophrenic pathophysiology; (b) 
muscarinic activity increases in an attempt to 
maintain this balance in the face of increasing 
dopaminergic activity that occurs in the psychotic 
phase of the illness; (c) the muscarinic cholinergic 
system exerts a damping effect on the emergence of 
positive symptoms associated with dopaminergic 
hyperactivity; and that (d) this compensatory in- 
crease in muscarinic activity is in turn accompan- 
ied by an intensification of negative symptoms 
during and following the psychotic phase of the 
illness. 
In the present study. we tested two major postu- 
lates of this model. We tested the prediction that 
muscarinic cholinergic activity is increased in schi- 
zophrenia by comparing the effect of biperiden, a 
specific M-l antimuscarinic agent, on rapid-eye- 
movement (REM) sleep in 12 drug-free schizo- 
phrenic patients and 12 matched normal controls. 
We evaluated the effect of cholinergic modulation 
on positive and negative symptoms by studying the 
effect of biperiden on positive and negative symp- 
toms in 30 otherwise drug-free schizophrenic 
patients. 
SUBJECTS AND METHODS 
The goals of this study were to: (I) compare the 
effects of an antimuscarinic anticholinergic agent 
on EEG sleep in 12 medication-free schizophrenic 
patients and age- and sex-matched normal con- 
trols; and (2) evaluate the effects of an anticholin- 
ergic agent on positive and negative symptoms 
in 30 otherwise medication-free schizophrenic 
patients. 
Sdject inclusion/e.\-elusion criteriu 
General inclusion/exclusion criteria for all research 
candidates were: (i) age= 18 45 years; (ii) in- 
formed consent; (iii) medication-free for at least 2 
weeks: (iv) absence of any serious medical illnesses 
or major physiological disturbances during the 3 
months prior to the study; (v) no primary sleep 
disorder as assessed by a sleep disorders question- 
naire and night 1 full montage sleep recording; (vi) 
absence of any medical condition that significantly 
affects sleep; (vii) no alcohol abuse or withdrawal 
in the past 3 months; and (viii) no use of cannabis. 
opiates, cocaine, or other ‘street drugs’ in the past 
3 months. 
Specific inclusion/exclusion criteria for schizo- 
phrenic patients were: (i) meets general inclusion, 
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exclusion criteria for all subjects, as listed above; 
(ii) meets DSM-III-R (American Psychiatric Asso- 
ciation, 1987) and RDC criteria (Spitzer et al., 
1978) for schizophrenia; (iii) currently meets cri- 
terion A of DSM-III-R (presence of characteristic 
psychotic symptoms); (iv) currently does not meet 
criteria for any other axis 1 or axis 2 disorder; and 
(v) has received no depot neuroleptics in the 6 
months prior to the study. 
Specific inclusion/exclusion criteria for normal 
controls were: (i) meets general inclusion/exclusion 
criteria for all subjects, as listed above; (ii) meets 
criteria for ‘never mentally ill’ (RDC) (Spitzer et 
al., 1978) with no prior or current treatment by a 
psychiatrist, psychologist, or other mental health 
professional; (iii) no family history of first-degree 
relatives with schizophrenia, other psychotic ill- 
nesses, or major mood (depressive/manic) dis- 
orders; and (iv) normal physical exam and screen- 
ing battery, including urine drug screen and EKG. 
Diqnostic ewluation procedures 
The following steps were taken to establish the 
diagnosis and inclusion/exclusion criteria: (a) un- 
structured independent clinical interviews con- 
ducted by a faculty psychiatrist or research fellow; 
(b) a structured psychiatric interview using the 
Schedule for Affective Disorders and Schizophre- 
nia (SADS) (Endicott and Spitzer, 1978) for 
schizophrenic patients and SADS-L (Spitzer and 
Endicott, 1979) for normal controls, both adminis- 
tered by formally trained research nurses with 
considerable experience in the administration of 
the SADS; (c) a comprehensive family diagnostic 
evaluation conducted by a psychiatric social 
worker that focused on the patient’s course of 
illness and that provided supplemental informa- 
tion from family members about the patient’s 
history, clinical features, and family history of 
psychiatric disorder; (d) a review of all previous 
available records; (e) comprehensive clinical and 
laboratory assessments to screen for physical dis- 
orders, that included a detailed review of systems, 
physical examination, chest X ray, hemoglobin, 
CBC with differential, electrolytes, liver functions, 
thyroid functions, VDRL, urinalysis and urine 
drug screen, electrocardiogram (EKG), and head 
CT scan; (f) a sleep disorders questionnaire admin- 
istered to assess for a primary sleep disorder. 
Additionally, the sleep-EEG on night 1 was a full- 
montage study to serve for adaptation and exclu- 
sion of a primary sleep disorder. 
Methods 
Following the diagnostic evaluation, schizophrenic 
patients and normal controls were included for 
further participation in the study only if they met 
all the inclusion and exclusion criteria and after 
informed consent had been obtained. The two 
studies were conducted in the following manner: 
(I) Sleep studies. 12 schizophrenic patients 
and age (f3 years)- and sex matched controls 
participated in the sleep studies. Each subject 
underwent three nights of polysomnography. 
Schizophrenic patients were studied in their own 
hospital beds by remote cable telemetry, while 
normal controls were studied in our sleep labora- 
tory. Subjects received no drugs on nights I and 2, 
but received 6/ 10 mg of biperiden on night 3. Sleep 
recordings started at approximately I I:00 p.m. 
(‘lights out’) and ended at 6:30 a.m. The first night 
was a standard full-montage polysomnographic 
study that included one EEG lead (C3/A2), one 
referential electro-oculogram (EOG) to record 
both horizontal and vertical eye movements, sub- 
mental electromyogram (EMG), respiratory moni- 
toring (nasal-oral thermistors, abdominal and 
thoracic strain gauges, and finger oximetry), elec- 
trocardiogram, and EMG of the anterior tibialis 
muscle. For the next two nights, only sleep staging 
the EKG monitoring was performed (EEG, EOG, 
EKG, and chin EMG). All polygraph records were 
scored visually on the basis of 1 min epochs 
according to Rechtschaffen-Kales criteria (Recht- 
schaffen et al., 1968) by experienced technicians 
blind to patient diagnosis and medication status. 
Sleep variables analyzed included sleep continuity, 
sleep architecture, and REM sleep indices. REM 
sleep latency (RL). defined as the time from sleep 
onset to the first REM period of at least 3 min 
duration minus intermittent awake minutes, was 
the principal dependent variable. Change in REM 
latency following biperiden (difference in REM 
latency between nights 2 and 3) was compared 
between the two groups by a Students’ t test. 
Change in REM latency following biperiden was 
employed as a measure of central cholinergic activ- 
ity since muscarinic cholinergic mechanisms play a 
significant role in regulating REM sleep (Sitaram 
et al., 1979; Berger et al., 1989). and assessing this 
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measure following a specific M-l antimuscarinic 
challenge may be a useful way of teasing out this 
cholinergic component. Two controls had signifi- 
cantly disrupted sleep following biperiden (with 
less than 20 min of sleep) and were therefore 
excluded from the analyses. The final sample for 
this study thus consisted of 12 schizophrenic 
patients and ten normal controls. 
(2) Effect of biperiden on positive and negative 
symptoms. For this study, the sample consisted of 
30 medication-free schizophrenic inpatients (19 
men and 11 women with a mean age= 30+ 6 
years). After having been maintained in a medica- 
tion-free state for at least 2 weeks, patients received 
6 or 10 mg of biperiden on night 1, and 4 mg 
biperiden p.o. bid for the next 2 days. Two nurse- 
clinician raters, blind to medication-status and 
rationale of the study, independently rated the 
patients on the l&item Brief Psychiatric Rating 
Scale (Overall and Gorham, 1962) before starting 
biperiden on biperiden day 1 (baseline) and after 2 
days of treatment with biperiden on day 4 (post- 
biperiden). Scores on BPRS items assessing motor 
retardation, blunted affect, and emotional with- 
drawal (rated 1 for not present to 7 for severe) were 
summed and used as the BPRS negative symptom 
cluster. These items collectively constitute the 
‘ANER’ factor (Guy, 1976; Hedlund and Viewig, 
1980). The BPRS items assessing conceptual dis- 
organization, suspiciousness, hallucinatory behav- 
ior, and unusual thought content were summed as 
the BPRS positive symptom cluster. These items 
collectively constitute the ‘THOT’ factor. The 
BPRS was employed to rate positive and negative 
symptomatology because it is a reliable, sensitive, 
and effective measure of psychopathology and of 
treatment-related symptom changes (Hedlund and 
Viewig, 1980). 
Biperiden was employed as the antimuscarinic 
anticholinergic agent because, as a relatively 
specific M-l antimuscarinic antagonist (Svyalahti et 
al., 1987; Eltze and Figala, 1988) it causes signifi- 
cantly fewer peripheral anticholinergic side-effects 
than other commonly used oral anticholinergic 
agents and is better tolerated (Avissar and 
Schreiber, 1989). Furthermore, M-l receptors are 
located in the brain areas considered relevant in 
schizophrenia (Bonner et al., 1987; Watson et al., 
1987) and are thus the receptor system most likely 
to be implicated in schizophrenic symptomatology. 
Since the usual daily dosage of biperiden in the 
treatment of parkinsonian symptoms is 4- 12 mg/ 
day, we elected to use 8 mg in two divided doses. 
The 4 day duration of the study was selected 
because (i) the effect of a single dose on symptoma- 
tology may be limited by the inability of the system 
to respond this quickly to anticholinergic modula- 
tion; and (ii) compensatory changes to the initial 
primary effect of biperiden might occur over a long 
period, thereby interfering with the evaluation of 
the primary effect. Paired two-tailed t tests were 
performed to compare the symptom ratings. 
RESULTS 
Effect of biperiden on REM latency in 
schizophrenic patients/normal controls 
Biperiden was fairly well tolerated by most schizo- 
phrenic patients and normal controls. As stated 
previously, two normal controls had less than 20 
min sleep on the biperiden night, necessitating their 
omission from the data analysis. Following biperi- 
den, mean REM latency increased from 75 2 11 
min to 134 f 20 min in normal controls and from 
67 f 16 to 102 & 19 in schizophrenic patients 
(Fig. 1). While there was no significant difference 
in baseline REM latency between the two groups, 
there was a statistical trend towards difference with 
regard to change in REM latency following biperi- 
den (t= 1.6, df= 10, P=O.OS, one-tailed), with 
schizophrenic patients showing less prolongation 
of REM latency. 
&fect of biperiden on positive/negative symptoms 
in schizophrenic patients 
The effect of 2 days treatment with 8 mg/day of 
biperiden on positive and negative symptoms was 
Fig. 1. Change in REM latency following biperiden 
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assessed in 30 otherwise drug-free schizophrenic 
inpatients. Positive and negative symptoms were 
monitored by the BPRS ‘THOT’ and ‘ANER’ 
factors, respectively. The 18item BPRS total scores 
at baseline ranged from 28 to 72 (mean k SD= 
48.3 k 8.5). In this study, inter-rater reliability coef- 
ficients (measured by the Pearson product moment 
correlations) between the two independent raters 
for the 18 individual BPRS items ranged from 
0.65-0.95, with a median of 0.83. The inter-rater 
reliability coefficients for the positive and negative 
symptom clusters were 0.90 and 0.85 respectively. 
Baseline positive symptom cluster scores ranged 
from 5 to 20 (mean + SD = 11.9 + 4.1). There was a 
significant increase in positive symptom severity 
following biperiden (t= 6.5, df=29, P<O.OOl), 
with post-biperiden positive symptom cluster scores 
ranging from 6 to 22 (mean + SD = 14.4 +4.5) (see 
Fig. 2). 
Baseline negative symptom cluster scores ranged 
from3.5to 17(mean+SD=8.7k3.8).Therewasa 
significant decrease in negative symptom severity 
following biperiden (t = - 2.1, df = 29, P < 0.05), 
with post-biperiden negative symptom cluster 
scores ranging from 4 to 18 (mean + SD = 8.0 i 3.6) 
(see Fig. 2). 
DISCUSSION 
These findings suggest that muscarinic cholinergic 
activity is increased in schizophrenia, and that this 
may be relevant to the expression of positive and 
negative symptoms, as suggested by the increase in 
positive symptoms and decrease in negative symp- 
toms following biperiden. Our findings are thus 
consistent with the hypothesized dopaminergic/ 
chohnergic model (Tandon and Greden, 1989) that 
postulates that: 
(a) central muscarinic cholinergic activity is in- 
creased in schizophrenia; 
(b) this increased cholinergic activity is associated 
with negative symptoms; and 
(c) decreasing cholinergic activity is associated 
with an increase in positive symptoms. 
Evidence for increased cholinergic activity in 
psychotic phase of schizophreniu 
The lesser increase in REM latency following 











Fig. 2. Change in positive and negative symptoms following 
biperiden in medication-free schizophrenics. 
to normal controls indicates that central choliner- 
gic activity may be increased in schizophrenia. 
Additional support for the presence of increased 
cholinergic activity in schizophrenia is provided by 
the significantly reduced REM latency in drug-free 
schizophrenic patients (Zarcone et al., 1987; Tan- 
don et al., 1989a), greater decrease in REM latency 
following RS-86 (a specific M-l muscarinic agent) 
in schizophrenic patients in comparison to normal 
controls (Berger et al., 1988; Hohagen et al., 1990) 
and the increased platelet phosphoinositide turn- 
over and diacylglycerol accumulation (both are 
secondary messengers of the M-l muscarinic sys- 
tem) (Baraban et al., 1989) in the psychotic phase 
of the illness. Post-mortem studies of cholinergic 
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parameters in brains of schizophrenic patients 
have so far yielded conflicting findings with regard 
to muscarinic receptor number. choline acetyl- 
transferase (ChAT) activity, and other measures 
(Domino et al., 1973; McGeer and McGeer. 1977; 
Watanabe et al.. 1983; Toru et al., 1988), with 
increase/decrease/and no change noted. 
Evidence,for ussociution hetltven increased 
muscarinic uctivity und negative symptoms 
The reduction in the severity of negative symptoms 
following biperiden implicates increased muscar- 
inic activity in the production of negative symp- 
toms. The phenomenological similarity between 
the ‘physostigmine syndrome’ and the negative 
syndrome (Davis et al., 1976; Greden et al., 1987), 
reduction of negative symptoms in chronic schizo- 
phrenic patients following anticholinergics (Fayen 
et al., 1988; Tandon et al., 1988). anticholinergic 
‘abuse’ by chronic schizophrenic patients with 
predominantly negative symptoms with energizing 
and socializing effects (Fisch et al., 1987; Wells et 
al.. 1989), association between decreased REM 
latency and negative symptom severity (Tandon et 
al., 1989a), and association between negative 
symptom severity and post-dexamethasone corti- 
sol levels (Saffer et al., 1985; Faustman et al., 1989: 
Tandon et al., 1989b) provide strong support for 
the implication of muscarinic hyperactivity in the 
production of negative symptoms. 
Evidence ,for association hettiseen reducing 
choiinergic activit)? and positive sjwptoms 
The significant increase in positive symptoms fol- 
lowing biperiden in otherwise medication-free 
schizophrenic patients indicates an association be- 
tween decreasing cholinergic activity and increas- 
ing positive symptoms in this phase of the illness. 
This association derives additional support from 
the finding that anticholinergics antagonize thera- 
peutic effects of neuroleptics only with reference to 
positive symptoms (Johnstone et al., 1983; Singh 
et al.. 1987; Johnstone et al., 1988) and that the 
exacerbation of positive symptoms in schizo- 
phrenic patients following methylphenidate (a 
dopamine agonist) is reversed by physostigmine 
(Janowsky et al., 1973). 
These data suggest that muscarinic cholinergic 
activity may be increased in the psychotic phase of 
schizophrenia and that this mechanism may be 
involved in the production of negative schizophrenic 
symptoms. These data also indicate that positive 
symptoms intensify when cholinergic activity is 
decreased in the acute psychotic phase of schizophre- 
nia. On the basis of this evidence, it appears that 
cholinergiq’dopaminergic balance may play an im- 
portant role in schizophrenic pathophysiology. and 
that the cholinergic system may exert a damping 
effect on the emergence of positive symptoms associ- 
ated with dopaminergic hyperactivity. Failure of the 
cholinergic system to return to baseline may be an 
important mechanism in the production of residual 
negative or ‘deficit’ symptoms. Fluctuations in cho- 
linergic activity at different stages of schizophrenia 
may partially explain the longitudinal course and 
prognosis of schizophrenic illness and may, in part, 
help to explain the variability and heterogeneity of 
schizophrenia (Tandon and Greden, 1990). 
We emphasize that we are not proposing an 
exclvsive monotransmitter (cholinergic) hypothesis 
of negative symptoms or schizophrenia. Indeed. 
dopaminergic mechanisms are obviously import- 
ant, serotonergic and noradrenergic mechanisms 
have been linked with negative symptoms, and 
other neurotransmitters may be involved as well. 
Exactly how these systems may interact remains 
unclear. Cholinergic hyperactivity may be involved 
in the production of negative symptoms in a 
subgroup of schizophrenic patients; alternatively, 
cholinergic interactions with other neurotrans- 
mitter systems may be important in the pathogene- 
sis of negative schizophrenic symptoms in certain 
phases of the illness. 
The hypothesis suggested is supported indirectly 
by data from several lines of research. is internally 
consistent, is congruent with current knowledge 
about schizophrenia and may explain some appar- 
ently discrepant findings. Despite the preliminary 
nature of current evidence, it probably is reason- 
able to pursue further the hypothesis that the 
cholinergic system plays a role in schizophrenic 
pathophysiology, and that muscarinic hyperactiv- 
ity may be an important mechanism in the produc- 
tion of negative schizophrenic symptoms. 
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